Study aim: Evaluation of the Effectiveness of Upadacitinib in Lichen Planus Design: A clinical trial with a control group, with parallel groups, double-blinded, randomized, phase 3 on 32 patients. Random Allocation software is used for randomization. Settings and conduct: This study will be conducted on patients with lichen planus who refer to the dermatology clinics of Shiraz University of Medical Sciences. Patients will be randomly divided into two intervention and control groups. The design will be outcome assessor blind. Participants/Inclusion and exclusion criteria: The inclusion criteria will be patients older than 16 years of age, weighing more than 40 kg, with cutaneous involvement of lichen planus and eGFR >60 , who are referred to the Dermatology Clinic of Shiraz University of Medical Sciences as newly diagnosed cases and have not received any topical or systemic treatment for lichen planus prior to enrollment in the study. The exclusion criteria will include patients with oral, nail, genital, or hair involvement of lichen planus; pregnant or breastfeeding women; evidence of renal or hepatic failure; a history of CVA, MI, DVT, PTE, or PUD; leukemia, lymphoma, or bone marrow failure; glucose-6-phosphate dehydrogenase (G6PD) deficiency; retinopathy; neuropsychiatric disorders; lymphopenia; or leukopenia. Intervention groups: Patients in the intervention group will receive the oral drug Opadacitinib Damonzia 15 mg (Kobel Daru Company) daily for 3 months. Main outcome variables: Lichen Planus Activity and Damage Index